Clinical Report: Ocular Complications from GLP-1 Receptor Agonists
Overview
GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide can lead to ocular complications, including diabetic retinopathy (DR) and non-arteritic anterior ischemic optic neuropathy (NAION). Baseline dilated retinal exams are essential before initiating therapy to assess risk factors.
Background
The use of GLP-1 RAs has increased due to their effectiveness in managing type 2 diabetes mellitus (T2DM) and associated cardiovascular risks. However, these medications are linked to ocular complications that necessitate careful monitoring. Understanding these risks is crucial for healthcare providers to ensure patient safety and optimize treatment outcomes.
Data Highlights
| Medication | DR Complications (%) | NAION Hazard Ratio | Wet AMD Risk (%) |
|---|---|---|---|
| Semaglutide | 3.0 (vs 1.8 placebo) | 4.28 (T2DM), 7.64 (obesity) | 0.2 (vs 0.1) |
| Tirzepatide | Higher odds in moderate DR/DME | N/A | N/A |
Key Findings
- Baseline dilated retinal exams are essential before starting GLP-1 RAs.
- Rapid A1C reduction may cause early worsening of diabetic retinopathy.
- 3% of semaglutide users developed DR complications compared to 1.8% on placebo.
- Tirzepatide is associated with higher odds of proliferative DR in patients with preexisting conditions.
- NAION risk is elevated in T2DM and obesity patients using semaglutide.
- Overall risk of wet AMD is low but higher among GLP-1 RA users over three years.
Clinical Implications
Healthcare providers should conduct comprehensive eye examinations before initiating GLP-1 RA therapy, especially in patients with preexisting diabetic retinopathy. Continuous monitoring is recommended for those at higher risk of ocular complications, and patients should be educated on the signs of NAION.
Conclusion
While GLP-1 RAs offer significant benefits in managing diabetes and cardiovascular risks, awareness of their potential ocular complications is essential for safe prescribing and patient management.
References
- American Academy of Optometry, 2025 -- What to Expect When You’re Expecting Ocular Complications From GLP-1 RAs
- JAMA Ophthalmology, 2025 -- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
- Glaucoma Physician, 2025 -- The Impact of GLP-1 Receptor Agonists on Ocular Disease
- glaucoma physician — The Impact of GLP-1 Receptor Agonists on Ocular Disease
- Retinal Physician — GLP-1 Receptor Agonists Linked to Increased nAMD Risk
- 2026 ADA Standards of Care
- Retinal Physician, 2025 -- GLP-1 Receptor Agonists Linked to Increased nAMD Risk
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis | Diabetes | JAMA Ophthalmology | JAMA Network
- Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
